BCM
MTNB icon

Bridgeway Capital Management’s Matinas BioPharma MTNB Stock Holding History

Bridgeway Capital Management’s Portfolio MTNB Stock Details MTNB Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2024
Q3 		– Sell
-530
Closed -$4.2K – 1298
2024
Q2 		$4.2K Hold
530
– – ﹤0.01% 1263
2024
Q1 		$7.18K Sell
530
-1,400
-73% -$16.6K ﹤0.01% 1302
2023
Q4 		$20.9K Hold
1,930
– – ﹤0.01% 1339
2023
Q3 		$12.5K Sell
1,930
-2,000
-51% -$24.6K ﹤0.01% 1353
2023
Q2 		$70.7K Sell
3,930
-7,138
-64% -$166K ﹤0.01% 1301
2023
Q1 		$260K Sell
11,068
-2,000
-15% -$50.5K 0.01% 1050
2022
Q4 		$327K Sell
13,068
-2,000
-13% -$66.5K 0.01% 972
2022
Q3 		$479K Hold
15,068
– – 0.01% 907
2022
Q2 		$595K Hold
15,068
– – 0.01% 842
2022
Q1 		$606K Hold
15,068
– – 0.01% 891
2021
Q4 		$761K Sell
15,068
-600
-4% -$32.1K 0.01% 853
2021
Q3 		$1.02M Hold
15,668
– – 0.02% 819
2021
Q2 		$607K Buy
15,668
+2,100
+15% +$90.3K 0.01% 1015
2021
Q1 		$712K Sell
13,568
-7,874
-37% -$528K 0.01% 989
2020
Q4 		$1.46M Buy
21,442
+4,530
+27% +$210K 0.03% 633
2020
Q3 		$648K Buy
16,912
+2,612
+18% +$104K 0.01% 806
2020
Q2 		$553K Buy
14,300
+7,500
+110% +$288K 0.01% 822
2020
Q1 		$204K Hold
6,800
– – ﹤0.01% 1053
2019
Q4 		$772K Hold
6,800
– – 0.01% 805
2019
Q3 		$214K Hold
6,800
– – ﹤0.01% 1172
2019
Q2 		$291K Hold
6,800
– – ﹤0.01% 1106
2019
Q1 		$371K Buy
+6,800
New +$366K ﹤0.01% 1109
2018
Q2 		– Sell
-3,780
Closed -$145K – 1440
2018
Q1 		$145K Hold
3,780
– – ﹤0.01% 1296
2017
Q4 		$219K Buy
3,780
+2,500
+195% +$161K ﹤0.01% 1268
2017
Q3 		$84K Sell
1,280
-1,220
-49% -$81.4K ﹤0.01% 1354
2017
Q2 		$211K Buy
+2,500
New +$336K ﹤0.01% 1279

Other funds holding MTNB

Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
HCM
Highbridge Capital Management New York $3.09B AUM 31.19% 1-Year Est. Return
SIG
Sargent Investment Group Bethesda, Maryland $759M AUM 28.58% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
Squarepoint
Squarepoint New York $85.1B AUM 20.93% 1-Year Est. Return
JEST
JTC Employer Solutions Trustee St Helier, Jersey $1.2B AUM 37.55% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
UBS Group
UBS Group Zurich, Switzerland $666B AUM 30.12% 1-Year Est. Return
SA
Sanctuary Advisors Indianapolis, Indiana $18.5B AUM 23.32% 1-Year Est. Return

Bridgeway Capital Management's MTNB Position: Q3 2024 in Review

Bridgeway Capital Management sold out of Matinas BioPharma (MTNB) in Q3 2024, closing a stake of 530 shares — an estimated $4.2K sold.

Bridgeway Capital Management first reported a position in MTNB in Q2 2017 and held it in 26 quarters. The position peaked at $1.46M in Q4 2020. 18 funds tracked by Wall St. Rank hold MTNB as of Q3 2024.

  • Bridgeway Capital Management reported no remaining Matinas BioPharma position as of Q3 2024 after selling out during the quarter.
  • Bridgeway Capital Management sold 530 Matinas BioPharma shares in Q3 2024, an estimated $4.2K.
  • Bridgeway Capital Management first reported a position in Matinas BioPharma in Q2 2017 and held it in 26 quarters.
  • Bridgeway Capital Management's Matinas BioPharma position peaked at $1.46M in Q4 2020.
  • 18 funds tracked by Wall St. Rank held Matinas BioPharma as of Q3 2024.

Based on Bridgeway Capital Management's 13F filing for Q3 2024, filed 14 Nov 2024.